The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection

Summary

This is an adaptive, Phase I/II study in 2 parts: Part 1 is to evaluate the Maximum Tolerable Dose (MTD) , tolerance, safety and pharmacokinetics of FB2001 in healthy subjects; Part 2 is to evaluate the safety, pharmacokinetics and efficacy of FB2001 in patients with moderate to severe COVID-19 disease.

Timeline

Start

2021-03-17

Primary completion

2022-08-12

Completion

2022-08-12

Drugs

Indications